- Poster Presentations Will Discuss Global Screening Data from Aimmune's Phase 3 PALISADE Trial and Current Approaches to Oral Immunotherapy -
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will present data on peanut allergy during poster sessions at two upcoming medical meetings.
ACAAI: At the American College of Asthma, Allergy and Immunology (ACAAI) Annual Scientific Meeting, taking place October 26-30, 2017, in Boston, Aimmune will present:
- P338: "Current Management and Use of Oral Immunotherapy (OIT) for Peanut Allergy in U.S. Patients" (Presenting author: J. Lieberman), Friday, October 27.
- P339: "International Comparisons of Patient Characteristics in a Phase 3 Study of AR101 for Peanut Allergy" (Presenting author: B. Vickery), Friday, October 27.
- P340: "Practice Considerations in Offering Peanut Oral Immunotherapy (OIT) in the United States" (Presenting author: D. Petroni), Friday, October 27.
Aimmune will also host a Corporate Symposium, "From Diagnosis to Potential Future Oral Immunotherapeutic Options: Understanding the Burden and Risk of Avoidance in Peanut Allergy," on Friday, October 27.
PAAM: At the European Academy of Allergy and Clinical Immunology's Pediatric Allergy and Asthma Meeting (PAAM), taking place October 26-28, 2017, in London, Aimmune will present:
- P104: "Current Management and Use of Oral Immunotherapy (OIT) for Peanut Allergy in Paediatric Patients in France, Germany, Italy, Spain, Switzerland and the United Kingdom" (Presenting author: A. Vereda), Friday, October 27.
Aimmune will also host a Corporate Symposium, "Peanut Allergy: Impact, Treatment and Defining Success," on Friday, October 27.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, is developing treatments for life-threatening food allergies. Aimmune's Characterized Oral Desensitization ImmunoTherapy (CODIT) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune's first investigational biologic product using CODIT, AR101 for the treatment of peanut allergy, has received the FDA's Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age and is currently being evaluated in Phase 3 clinical trials. For more information, please see www.aimmune.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171019005406/en/
Contacts:
Aimmune Therapeutics, Inc.
Investors
Laura Hansen, Ph.D., 650-396-3814
lhansen@aimmune.com
or
Media
Stephanie Yao, 650-351-6479
syao@aimmune.com